文献速递其他结缔组织病

欧洲硬皮病试验与研究队列中系统性硬化症患者聚类分析确定的表型及其生存

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2019-08-12

部分组类似dcSSc或lcSSc原型,另一些组具有独特特征;预后因组而异,器官损伤的存在显著影响生存,与皮肤受累范围无关。结论提示仅按皮肤受累分型可能无法完全捕捉疾病异质性,分组时应考虑器官损伤和抗体谱。

要点

  • 聚类分析识别出2个中等稳定性聚类,并探索性划分出6个临床与预后异质的同质组。
  • 部分组类似dcSSc或lcSSc原型,另一些组(如多数lcSSc伴高内脏损伤和抗拓扑异构酶抗体)具独特特征。
  • 器官损伤显著影响生存,与皮肤受累范围无关,提示分型需结合器官损伤和抗体谱。

核心结论

  • 仅按皮肤受累范围划分SSc亚型可能无法完全捕捉疾病异质性,器官损伤和抗体谱应纳入同质患者组的识别。

主要发现

  • 聚类分析首先 delineation 出2个中等稳定性的聚类;进一步探索性分析识别出6个在临床特征、自身抗体谱和死亡率上存在差异的同质组。
  • 部分组类似dcSSc或lcSSc原型,另一些组具有独特特征,如多数lcSSc患者伴高内脏损伤率和抗拓扑异构酶抗体。
  • 预后因组而异,器官损伤的存在显著影响生存,无论皮肤受累范围如何。

临床怎么用

  • 临床评估SSc患者时,除皮肤受累范围外,应关注器官损伤和自身抗体谱以识别预后不同的同质组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. METHODS: A total of 11,318 patients were registered in the EUSTAR database, and 6,927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. RESULTS: Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. CONCLUSION: Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Sobanski V, Giovannelli J, Allanore Y, et al. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis Rheumatol. 2019. PMID: 30969034. doi:10.1002/art.40906

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。